Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia

被引:8
|
作者
Najarian, Dean [1 ]
Turkoz, Ibrahim [2 ,8 ]
Knight, R. Karl
Galderisi, Silvana [3 ]
Lamaison, Hector F. [4 ]
Zalitacz, Piotr [5 ]
Aravind, Suresh [2 ,7 ]
Richarz, Ute [6 ]
机构
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Titusville, NJ USA
[3] Univ Campania Luigi Vanvitelli, Naples, Italy
[4] Natl Univ La Plata UNLP, Dept Psychiat, Buenos Aires, Argentina
[5] Gorlice Specialist Hosp, Psychiat Unit, Gorlice, Poland
[6] Cilag Int, Janssen Res & Dev, Gubelstr, Zug, Switzerland
[7] Dural Consulting LLC, St Petersburg, FL USA
[8] Janssen Res & Dev LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
来源
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2023年
关键词
Long-term efficacy; schizophrenia; long-acting injectable; open-label extension; paliperidone palmitate 6-month; ACTING INJECTABLE ANTIPSYCHOTICS; PALMITATE; RELAPSE; REHOSPITALIZATION; NONADHERENCE; MEDICATION; ADHERENCE; PLACEBO;
D O I
10.1093/ijnp/pyad028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, open-label extension (OLE; NCT04072575) of this DB study. Methods Participants who completed the DB study without relapse were enrolled and followed-up every 3 months up to 2 years. Participants received 4 PP6M gluteal injections (700/1000 mg eq.) at baseline, 6-month, 12-month, and 18-month visits. Efficacy endpoints included assessment of relapse, Positive and Negative Syndrome Scale total score, Personal and Social Performance score, and Clinical Global Impression-Severity scale change from baseline. Safety was assessed by treatment-emergent adverse events (TEAEs), physical examinations, and laboratory tests. Results Of 178 participants enrolled, 154 (86.5%) completed the OLE (mean age: 40.4 years, men: 70.8%; mean duration of PP6M exposure during OLE: 682.1 days). Overall, 7/178 (3.9%) participants relapsed between 20 and 703 days after enrolment. Mean (SD) changes from baseline to endpoint were as follows: Positive and Negative Syndrome Scale total score, 0.7 (8.22); Clinical Global Impression-Severity, 0.0 (0.51); and Personal and Social Performance Scale, 0.5 (7.47). Overall, 111/178 participants (62.4%) reported & GE;1 TEAE; most common (>5%) TEAEs were headache (13.5%) and increased blood prolactin/hyperprolactinemia (18.0%); 8/178 (4.5%) participants experienced serious TEAEs, and 6/178 (3.4%) participants withdrew due to TEAEs. No deaths were reported. Conclusions The relapse rate observed with PP6M during the 2-year OLE was low (3.9%). Clinical and functional improvements demonstrated in the DB study were maintained during OLE, and no new safety concerns were identified.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 50 条
  • [1] Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia
    Najarian, D.
    Turkoz, I.
    Galderisi, S.
    Lamaison, H. F.
    Zalitacz, P.
    Aravind, S.
    Richarz, U.
    EUROPEAN PSYCHIATRY, 2023, 66 : S136 - S136
  • [2] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
  • [3] Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study
    Ketter, Terence A.
    Amchin, Jess
    Frye, Mark A.
    Gross, Nicholas
    JOURNAL OF AFFECTIVE DISORDERS, 2016, 197 : 51 - 57
  • [4] Safety and effectiveness of long-term treatment with lurasidone in children and adolescents with bipolar depression: A 6-month interim analysis of a 2-year open-label extension study
    Chang, K.
    Tocco, M.
    Goldman, R.
    Pikalov, A.
    Deng, L.
    Cucchiaro, J.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2018, 48 : S81 - S82
  • [5] Efficacy and safety of lurasidone in adolescents with schizophrenia: analysis of a 2-year, open-label extension study
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Ling, D.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S275 - S276
  • [6] Efficacy and safety of lurasidone in adolescents with schizophrenia: Results of a 2-year, open-label extension study
    Goldman, R.
    Correll, C.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S88 - S89
  • [7] Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension
    Worm, Margitta
    Rak, Sabina
    Samolinski, Boleslaw
    Antila, Jukka
    Hoiby, Ann-Sofi
    Kruse, Brigitte
    Lipiec, Agnieszka
    Rudert, Michael
    Valovirta, Erkka
    CLINICAL AND EXPERIMENTAL ALLERGY, 2019, 49 (04): : 516 - 525
  • [8] Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia:: a 2-year, open-label extension study
    Luetjohann, D.
    von Bergmann, K.
    Sirah, W.
    Macdonell, G.
    Johnson-Levonas, A. O.
    Shah, A.
    Lin, J.
    Sapre, A.
    Musliner, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (10) : 1499 - 1510
  • [9] LONG-TERM SAFETY AND TOLERABILITY OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A 6-MONTH, OPEN-LABEL STUDY
    Stahl, Steven M.
    Cucchiaro, Josephine
    Simonelli, D.
    Severs, J.
    Loebel, A.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 322 - 322
  • [10] One-Year Efficacy and Safety Study of a 1.62% Testosterone Gel in Hypogonadal Men: Results of a 182-Day Open-Label Extension of a 6-Month Double-Blind Study
    Kaufman, Joel M.
    Miller, Michael G.
    Fitzpatrick, Sherahe
    McWhirter, Cecilia
    Brennan, John J.
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 (04): : 1149 - 1161